Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.

Chin-Chou WangLi-Chung ChiuJia-Shiuan JuYu-Ching Lin Yueh-Fu Fang Cheng-Ta Yang Ping-Chih Hsu

Published in: Vaccines (2021)

Consolidation durvalumab is effective and safe for post-CCRT unresectable stage III NSCLC in clinical practice, but EGFR mutation is an unfavorable factor for consolidation durvalumab. Thus, searching for a better consolidation therapy for EGFR-mutated patients is warranted.

Keyphrases

small cell lung cancer
locally advanced
clinical practice
epidermal growth factor receptor
rectal cancer
end stage renal disease
tyrosine kinase
ejection fraction
newly diagnosed
single cell
liver metastases
advanced non small cell lung cancer
clinical trial
patient reported outcomes